SL-28 for Advanced Solid Tumours

Conditions

• Bladder Cancer
• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Esophageal Cancer
• Head & Neck Cancer
• Intestinal Cancer
• Liver Cancer
• Lung Adenocarcinoma
• Lung Cancer (NSCLC)
• Lung Cancer (Non-Small Cell)
• Melanoma (Skin Cancer)
• Ovarian Cancer
• Pancreas Cancer, Metastatic
• Pancreas Carcinoma
• Prostate Cancer
• Renal Cancer
• Stomach (Gastric) Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• SL-28 — BIOLOGICAL
  Doses administered: 3×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
• SL-28 — BIOLOGICAL
  Doses administered: 6×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
• SL-28 — BIOLOGICAL
  Doses administered: to-be-determeined-later Mode of administration: intravenous push

Study Details

Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.

Key Dates

First listed

Jan 14, 2026

Start date

Jul 13, 2026

Status verified

Jul 2026

Primary completion

Jan 1, 2027

Completion

Mar 1, 2027

Study Design

Enrollment

60 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: SL-28 Low Dose
• Experimental: SL-28 Intermediate Dose
• Experimental: SL-28 High Dose

Primary Outcome Measure

Number of participants with treatment-emergent adverse events [ Time Frame: 12 weeks ]

Central Contacts

• George Tetz, MD, PhD
  16466173088
  [email protected]

Find similar trials

Related Studies

• Evaluation for NCI Surgery Branch Clinical Research Protocols
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
  Recruiting · Northwestern University · Chicago, Illinois
• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Collection of Blood From Patients With Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland